Mersana Therapeutics, Inc..
MRSN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on discovering and developing a pipeline of antibody-drug conjugates (ADCs) for cancer patients. The company's pipeline includes Upifitamab Rilsodotin (UpRi), an ADC targeting NaPi2b-expressing tumors and in clinic...Show More
Better Health for All
0
No evidence available to assess Mersana Therapeutics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Mersana Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
40
The company's CEO-to-median-worker pay ratio is 10:1.
1
Mersana Therapeutics announced a 55% staff layoff, which will reduce its headcount from 102 full-time employees by the end of Q3 2025.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess Mersana Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Mersana Therapeutics, Inc. on Honest & Fair Business.
Kind to Animals
-60
Mersana Therapeutics employs *in vitro* cytotoxicity, cell binding, and ADC internalization assays for early-stage assessments.
1
However, extensive *in vivo* animal testing is conducted for efficacy and toxicology studies, indicating that non-animal methods are rarely used for complex endpoints.
2
Toxicology studies involved 16 male and 16 female Sprague-Dawley rats per dose group and 6 male and 6 female cynomolgus monkeys per dose group.
3
Efficacy studies used groups of 8-10 mice.
4
All animal procedures comply with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare, with protocols approved by Institutional Animal Care and Use Committees.
5
The company's policy focuses on compliance with existing regulations, but does not articulate a clear intent for reduction or elimination of animal testing, nor does it prohibit non-essential testing.
6
No War, No Weapons
0
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer patients.
1
The provided articles detail collaboration and licensing agreements within the pharmaceutical sector for research, development, and commercialization of ADCs.
2
There is no evidence in the articles to suggest any involvement in arms manufacturing, military contracts, dual-use technology with military applications, sales to sanctioned regimes, or any other activities related to war or weapons. Therefore, all KPIs related to the 'No War, No Weapons' value are assessed as N/A, indicating that these activities are not part of the company's core business or operations.
Planet-Friendly Business
-10
Mersana Therapeutics recycled 68% of its laboratory waste in 2022.
1
The company also reported a 15.3% reduction in carbon emissions and a 16.5% reduction in water consumption in 2022.
2
Hazardous chemical usage was reduced by 22% in 2022.
3
The company invested $1.2 million in sustainable research infrastructure in 2022 and $1.1 million in climate adaptation in 2023.
4
Respect for Cultures & Communities
0
The provided articles, including the company's pipeline details and careers page, explicitly state that they contain no quantitative data or specific information relevant to community engagement, cultural sensitivity, or social responsibility initiatives.
1
Therefore, no evidence was found to assess Mersana Therapeutics against any of the KPIs for 'Respect for Cultures & Communities'.
Safe & Smart Tech
0
No evidence available to assess Mersana Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Mersana Therapeutics, Inc. on Zero Waste & Sustainable Products.